Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Alzheimer's disease (AD) is the most common neurodegenerative disorder seen in age-
dependent dementia. There is currently no effective treatment for AD, which may be …

The amyloid cascade hypothesis is a useful framework for therapeutic development in
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …

Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the
comorbidity of these brain disorders in aging individuals represents a significant challenge …

Alzheimer's disease (AD) is an insidious and progressive neurodegenerative disorder that
affects millions of people worldwide. Although the pathogenesis remains obscure, there are …

Abstract Alzheimer's disease (AD), characterized by the β-amyloid protein (Aβ) deposition
and tau hyperphosphorylation, is the most common dementia with uncertain etiology. The …

Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms,
including memory impairments and cognitive deficits. Hallmarks of AD pathology are …

Excitatory glutamatergic neurotransmission via N-methyl-d-aspartate receptor (NMDAR) is
critical for synaptic plasticity and survival of neurons. However, excessive NMDAR activity …